MannKind Corporation (Nasdaq: MNKD) Q2 2026 revenue rises 43% as costs drive loss
Rhea-AI Filing Summary
MannKind Corporation reported Q2 2026 total revenues of $109,374 (thousands), a 43% increase from Q2 2025, driven by the addition of Furoscix, higher collaborations and services revenue, and royalties tied to Tyvaso DPI. Commercial product sales were $41,982 (thousands), including Furoscix net sales of $22,191 (thousands) and Afrezza net sales of $17,021 (thousands). For the first six months of 2026, total revenues reached $199,544 (thousands), up 29% year over year.
Higher cost of goods, research and development, and selling, general and administrative expenses, largely associated with Furoscix and pipeline advancement, led to a Q2 2026 net loss of $19,032 (thousands), or $0.06 per basic share, compared with net income of $668 (thousands) a year earlier. Non-GAAP adjusted net loss was $2,660 (thousands) versus non-GAAP income of $13,901 (thousands). Cash, cash equivalents and investments totaled $111 million as of June 30, 2026, and a $50 million private placement closed on July 24, 2026 to fund a $45 million contingent value right payment following FDA approval of the Furoscix ReadyFlow autoinjector. During 2026, MannKind also received FDA approval for a pediatric indication for Afrezza and reported positive Phase 1b data for its nintedanib DPI program while preparing an IND for ralinepag DPI.
Positive
- Total revenues rose 43% year over year in Q2 2026 to $109,374 (thousands), with commercial product sales and collaborations/royalties expanding, helped by the addition of Furoscix and increased Tyvaso DPI-related royalties.
- Six-month 2026 revenues grew 29% to $199,544 (thousands), reflecting broader contributions from Furoscix, higher collaborations and services revenue, and growing royalty streams.
Negative
- Profitability deteriorated, with a Q2 2026 net loss of $19,032 (thousands) versus prior-year income, as selling, general and administrative expenses nearly doubled to $58,302 (thousands).
- Non-GAAP results also weakened, showing an adjusted net loss of $2,660 (thousands) for Q2 2026 compared with non-GAAP income of $13,901 (thousands) in Q2 2025.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Furoscix ReadyFlow Autoinjector medical
contingent consideration financial
liability for sale of future royalties financial
IPR&D - ReadyFlow Formulation financial
non-GAAP adjusted net (loss) income financial
Breakthrough T1D grant medical
Earnings Snapshot
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were MannKind (MNKD) Q2 2026 revenues and how did they change year over year?
Did MannKind (MNKD) report a profit or loss for Q2 2026, and what was EPS?
How did Furoscix and Afrezza perform for MannKind (MNKD) in Q2 2026?
What key FDA approvals and clinical milestones did MannKind (MNKD) achieve in 2026?
What is MannKind (MNKD)'s cash position and recent financing activity?
How do MannKind (MNKD)'s non-GAAP Q2 2026 results compare with GAAP figures?
What were MannKind (MNKD)'s operating expense trends in Q2 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 5, 2026, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1 |
Press release dated August 5, 2026 |
|
|
Exhibit 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MannKind Corporation |
|
|
|
|
|
|
|
Date: August 5, 2026 |
By: |
/s/ David Thomson, Ph.D., J.D. |
|
|
David Thomson, Ph.D., J.D. |
|
|
Corporate Vice President, General Counsel and Secretary |
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)
a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the second quarter of 2026, and provided a business update.
“This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026,” said Michael Castagna, Chief Executive Officer of MannKind. “The two recent FDA approvals are expected to fuel our near-term growth opportunities to help patients living with diabetes, heart failure and CKD. The positive Phase 1b INFLO-1 results for MNKD-201 reduces development risk and strengthens our confidence in the ability of our platform to help people living with IPF and other fibrotic diseases. Together, these milestones validate our diversification strategy and position MannKind for sustainable growth.”
Business Update and Upcoming Milestones
Commercial Products
Furoscix
Afrezza
Development
Nintedanib DPI (MNKD-201)
Ralinepag DPI (MNKD-1501)
Corporate Update
Second Quarter 2026 Financial Results
Revenues
|
|
Three Months |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
$ Change |
|
|
% Change |
|
||||
Revenues |
|
(Dollars in thousands) |
|
|||||||||||||
Afrezza |
|
|
17,021 |
|
|
|
18,329 |
|
|
|
(1,308 |
) |
|
|
(7 |
%) |
Furoscix |
|
|
22,191 |
|
|
|
— |
|
|
|
22,191 |
|
|
N/A |
|
|
V-Go® |
|
|
2,770 |
|
|
|
4,125 |
|
|
|
(1,355 |
) |
|
|
(33 |
%) |
Collaborations and services |
|
|
35,022 |
|
|
|
22,845 |
|
|
|
12,177 |
|
|
|
53 |
% |
Royalties |
|
|
32,370 |
|
|
|
31,228 |
|
|
|
1,142 |
|
|
|
4 |
% |
Total revenues |
|
$ |
109,374 |
|
|
$ |
76,527 |
|
|
$ |
32,847 |
|
|
|
43 |
% |
Total revenues for the second quarter of 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to increased product sold to UT and revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.
Operating Expenses and Other Financial Highlights
Six Months Ended June 30, 2026
Revenues
|
|
Six Months |
|
|||||||||||||
|
|
2026 |
|
|
2025 |
|
|
$ Change |
|
|
% Change |
|
||||
Revenues |
|
(Dollars in thousands) |
|
|||||||||||||
Afrezza |
|
|
32,294 |
|
|
|
33,216 |
|
|
|
(922 |
) |
|
|
(3 |
%) |
Furoscix |
|
|
37,684 |
|
|
|
— |
|
|
|
37,684 |
|
|
N/A |
|
|
V-Go |
|
|
5,911 |
|
|
|
8,211 |
|
|
|
(2,300 |
) |
|
|
(28 |
%) |
Collaborations and services |
|
|
58,536 |
|
|
|
52,221 |
|
|
|
6,315 |
|
|
|
12 |
% |
Royalties |
|
|
65,119 |
|
|
|
61,233 |
|
|
|
3,886 |
|
|
|
6 |
% |
Total revenues |
|
$ |
199,544 |
|
|
$ |
154,881 |
|
|
$ |
44,663 |
|
|
|
29 |
% |
Total revenues for the six months ended June 30, 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to an increase in revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.
Operating Expenses and Other Financial Highlights
Conference Call and Webcast
MannKind will host a conference call and webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours after the call and accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Forward-Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the timing for expected commercial availability of Furoscix ReadyFlow and the broadened growth potential for Furoscix; the timing of a planned IND filing of ralinepag DPI; expectations regarding MannKind’s ongoing and planned clinical trials and nonclinical studies; and our being positioned for sustainable growth. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential,” “prepare,” “opportunity” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; risks associated with competition; manufacturing risks; market adoption risks; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Tyvaso DPI is a trademark of United Therapeutics Corporation.
AFREZZA, FUROSCIX, FUROSCIX READYFLOW, MANNKIND, and V-GO are trademarks of MannKind Corporation.
MannKind Contacts:
Investor Relations
Kate Miranda
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
Email: media@mnkd.com
MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
Three Months |
|
|
Six Months |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
|
|
(In thousands except per share data) |
|
|||||||||||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Commercial product sales |
|
$ |
41,982 |
|
|
$ |
22,454 |
|
|
$ |
75,889 |
|
|
$ |
41,427 |
|
Collaborations and services |
|
|
35,022 |
|
|
|
22,845 |
|
|
|
58,536 |
|
|
|
52,221 |
|
Royalties |
|
|
32,370 |
|
|
|
31,228 |
|
|
|
65,119 |
|
|
|
61,233 |
|
Total revenues |
|
|
109,374 |
|
|
|
76,527 |
|
|
|
199,544 |
|
|
|
154,881 |
|
Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of goods sold – commercial, excluding amortization of acquired intangible assets |
|
|
14,409 |
|
|
|
4,607 |
|
|
|
21,917 |
|
|
|
8,375 |
|
Cost of revenue – collaborations and services |
|
|
15,131 |
|
|
|
15,961 |
|
|
|
25,094 |
|
|
|
29,709 |
|
Research and development |
|
|
18,001 |
|
|
|
13,675 |
|
|
|
35,232 |
|
|
|
24,697 |
|
Selling, general and administrative |
|
|
58,302 |
|
|
|
31,622 |
|
|
|
112,389 |
|
|
|
56,636 |
|
Amortization of acquired intangible assets |
|
|
4,367 |
|
|
|
— |
|
|
|
8,734 |
|
|
|
— |
|
(Gain) loss on foreign currency transaction |
|
|
(486 |
) |
|
|
5,363 |
|
|
|
(1,804 |
) |
|
|
7,872 |
|
Total expenses |
|
|
109,724 |
|
|
|
71,228 |
|
|
|
201,562 |
|
|
|
127,289 |
|
(Loss) income from operations |
|
|
(350 |
) |
|
|
5,299 |
|
|
|
(2,018 |
) |
|
|
27,592 |
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income, net |
|
|
1,022 |
|
|
|
1,832 |
|
|
|
2,452 |
|
|
|
3,788 |
|
Interest expense |
|
|
(11,894 |
) |
|
|
(285 |
) |
|
|
(19,372 |
) |
|
|
(4,930 |
) |
Interest expense on liability for sale of future royalties |
|
|
(510 |
) |
|
|
(3,473 |
) |
|
|
(3,073 |
) |
|
|
(7,050 |
) |
Interest expense on financing liability |
|
|
(2,414 |
) |
|
|
(2,433 |
) |
|
|
(4,807 |
) |
|
|
(4,843 |
) |
Loss on settlement of debt |
|
|
— |
|
|
|
— |
|
|
|
(917 |
) |
|
|
— |
|
Other expense |
|
|
(4,992 |
) |
|
|
— |
|
|
|
(7,769 |
) |
|
|
— |
|
Total other expense |
|
|
(18,788 |
) |
|
|
(4,359 |
) |
|
|
(33,486 |
) |
|
|
(13,035 |
) |
(Loss) income before income tax (benefit) expense |
|
|
(19,138 |
) |
|
|
940 |
|
|
|
(35,504 |
) |
|
|
14,557 |
|
Income tax (benefit) expense |
|
|
(106 |
) |
|
|
272 |
|
|
|
147 |
|
|
|
731 |
|
Net (loss) income |
|
$ |
(19,032 |
) |
|
$ |
668 |
|
|
$ |
(35,651 |
) |
|
$ |
13,826 |
|
Net (loss) income per share – basic |
|
$ |
(0.06 |
) |
|
$ |
0.00 |
|
|
$ |
(0.12 |
) |
|
$ |
0.05 |
|
Weighted average shares used to compute net (loss) income |
|
|
309,191 |
|
|
|
304,954 |
|
|
|
308,732 |
|
|
|
304,222 |
|
Net (loss) income per share – diluted |
|
$ |
(0.06 |
) |
|
$ |
0.00 |
|
|
$ |
(0.12 |
) |
|
$ |
0.04 |
|
Weighted average shares used to compute net (loss) income |
|
|
309,191 |
|
|
|
311,484 |
|
|
|
308,732 |
|
|
|
312,381 |
|
MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
||
|
|
(In thousands except share |
|
|||||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
52,929 |
|
|
$ |
74,882 |
|
Short-term investments |
|
|
58,201 |
|
|
|
96,464 |
|
Accounts receivable, net |
|
|
43,207 |
|
|
|
38,367 |
|
Inventory |
|
|
44,419 |
|
|
|
35,313 |
|
Prepaid expenses and other current assets |
|
|
46,956 |
|
|
|
46,553 |
|
Total current assets |
|
|
245,712 |
|
|
|
291,579 |
|
Restricted cash |
|
|
749 |
|
|
|
745 |
|
Long-term investments |
|
|
— |
|
|
|
5,012 |
|
Property and equipment, net |
|
|
85,160 |
|
|
|
82,423 |
|
Goodwill |
|
|
67,595 |
|
|
|
67,595 |
|
Developed technology - on-body infusor |
|
|
181,389 |
|
|
|
190,027 |
|
IPR&D - ReadyFlow Formulation |
|
|
129,600 |
|
|
|
129,600 |
|
Other intangible assets |
|
|
4,976 |
|
|
|
5,072 |
|
Other assets |
|
|
17,123 |
|
|
|
20,129 |
|
Total assets |
|
$ |
732,304 |
|
|
$ |
792,182 |
|
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS' DEFICIT |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
11,042 |
|
|
$ |
9,034 |
|
Accrued expenses and other current liabilities |
|
|
60,768 |
|
|
|
64,628 |
|
Senior convertible notes – current |
|
|
— |
|
|
|
36,280 |
|
Liability for sale of future royalties – current |
|
|
14,292 |
|
|
|
14,298 |
|
Contingent consideration – current |
|
|
34,015 |
|
|
|
21,132 |
|
Financing liability – current |
|
|
10,486 |
|
|
|
10,328 |
|
Deferred revenue – current |
|
|
11,085 |
|
|
|
15,331 |
|
Recognized loss on purchase commitments – current |
|
|
1,210 |
|
|
|
— |
|
Total current liabilities |
|
|
142,898 |
|
|
|
171,031 |
|
Liability for sale of future royalties – long term |
|
|
133,552 |
|
|
|
136,985 |
|
Financing liability – long term |
|
|
92,497 |
|
|
|
93,092 |
|
Deferred revenue – long term |
|
|
36,857 |
|
|
|
39,977 |
|
Recognized loss on purchase commitments – long term |
|
|
62,922 |
|
|
|
65,952 |
|
Operating lease liability |
|
|
9,687 |
|
|
|
10,689 |
|
Contingent consideration – long term |
|
|
— |
|
|
|
5,114 |
|
Milestone liabilities |
|
|
2,003 |
|
|
|
2,003 |
|
Term loan |
|
|
319,085 |
|
|
|
318,361 |
|
Total liabilities |
|
|
799,501 |
|
|
|
843,204 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders' deficit: |
|
|
|
|
|
|
||
Undesignated preferred stock, $0.01 par value – 10,000,000 shares authorized; |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value – 800,000,000 shares authorized; |
|
|
3,099 |
|
|
|
3,078 |
|
Additional paid-in capital |
|
|
3,161,330 |
|
|
|
3,141,741 |
|
Accumulated other comprehensive (loss) income |
|
|
(19 |
) |
|
|
115 |
|
Accumulated deficit |
|
|
(3,231,607 |
) |
|
|
(3,195,956 |
) |
Total stockholders' deficit |
|
|
(67,197 |
) |
|
|
(51,022 |
) |
Total liabilities and stockholders' deficit |
|
$ |
732,304 |
|
|
$ |
792,182 |
|
Non-GAAP Measures
To supplement our condensed consolidated financial statements presented under GAAP, we are presenting non-GAAP net (loss) income and non-GAAP net (loss) income per share – basic, which are non-GAAP financial measures. We are providing these non-GAAP financial measures to disclose additional information to facilitate the comparison of past and present operations, and they are among the indicators management uses as a basis for evaluating our financial performance. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results, provide management and investors with an additional understanding of our business operating results, including underlying trends.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that we may exclude for purposes of our non-GAAP financial measures; and we may in the future
cease to exclude items that we have historically excluded for purposes of our non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized definitions of non- GAAP financial measures, the non-GAAP financial measures as used by us in this report have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
The following table reconciles our financial measures for net (loss) income and net (loss) income per share ("EPS") for basic weighted average shares as reported in our condensed consolidated statement of operations to a non-GAAP presentation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
|
Three Months |
|
|
Six Months |
|
|||||||||||||||||||||||||||||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|||||||||||||||||||||||||||||||
|
|
Net Loss |
|
|
Basic EPS |
|
|
Net Income |
|
|
Basic EPS |
|
|
Net Loss |
|
|
Basic EPS |
|
|
Net Income |
|
|
Basic EPS |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
GAAP reported net (loss) income |
|
$ |
(19,032 |
) |
|
$ |
(0.06 |
) |
|
$ |
668 |
|
|
$ |
0.00 |
|
|
$ |
(35,651 |
) |
|
$ |
(0.12 |
) |
|
$ |
13,826 |
|
|
$ |
0.05 |
|
|||||||||||
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Stock compensation |
|
|
10,226 |
|
|
|
0.03 |
|
|
|
7,520 |
|
|
|
0.03 |
|
|
|
16,681 |
|
|
|
0.05 |
|
|
|
12,905 |
|
|
|
0.04 |
|
|||||||||||
Interest expense on liability for sale of future royalties |
|
|
510 |
|
|
|
0.00 |
|
|
|
3,473 |
|
|
|
0.01 |
|
|
|
3,073 |
|
|
|
0.01 |
|
|
|
7,050 |
|
|
|
0.02 |
|
|||||||||||
Sold portion of royalty revenue (1) |
|
|
(3,237 |
) |
|
|
(0.01 |
) |
|
|
(3,123 |
) |
|
|
(0.01 |
) |
|
|
(6,512 |
) |
|
|
(0.02 |
) |
|
|
(6,123 |
) |
|
|
(0.02 |
) |
|||||||||||
(Gain) loss on foreign currency transaction |
|
|
(486 |
) |
|
|
0.00 |
|
|
|
5,363 |
|
|
|
0.02 |
|
|
|
(1,804 |
) |
|
|
(0.01 |
) |
|
|
7,872 |
|
|
|
0.03 |
|
|||||||||||
Amortization of intangible assets acquired |
|
|
4,367 |
|
|
|
0.01 |
|
|
|
— |
|
|
|
— |
|
|
|
8,734 |
|
|
|
0.03 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Change in fair value of contingent consideration |
|
|
4,992 |
|
|
|
0.02 |
|
|
|
— |
|
|
|
— |
|
|
|
7,769 |
|
|
|
0.03 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Loss on settlement of debt |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
917 |
|
|
|
0.00 |
|
|
|
— |
|
|
|
— |
|
|||||||||||
Non-GAAP adjusted net (loss) income |
|
$ |
(2,660 |
) |
|
$ |
(0.01 |
) |
|
$ |
13,901 |
|
|
$ |
0.05 |
|
|
$ |
(6,793 |
) |
|
$ |
(0.03 |
) |
|
$ |
35,530 |
|
|
$ |
0.12 |
|
|||||||||||
Weighted average shares used to compute net (loss) income per share – basic |
|
|
309,191 |
|
|
|
|
|
|
304,954 |
|
|
|
|
|
|
308,732 |
|
|
|
|
|
|
304,222 |
|
|
|
|
|||||||||||||||